Enwei Medicine: Announcement on the progress of co-investment and establishment of funds with professional investment institutions

Securities code: 301331 Securities abbreviation: Enwei Pharmaceuticals Announcement number: 2026-034

Enwei Pharmaceutical Co., Ltd.

Announcement on the progress of joint investment and establishment of funds with professional investment institutions

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.

1. Overview of co-investment with professional investment institutions

Enwei Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Enwei Pharmaceutical") serves as a limited partner in 2026 In May 2018, we entered into cooperation with Shanghai Proxima Business Services Partnership (Limited Partnership) (hereinafter referred to as "Proxima Business"), Shanghai Future Qidian Private Equity Investment Fund Partnership (Limited Partnership), Shanghai Jingtou Equity Investment Fund Management Co., Ltd., Shanghai Shibei High-tech Co., Ltd., Hangzhou Linkong Equity Investment Co., Ltd., Naxin Holdings Co., Ltd., Zhao Jianlun, Sun Jiansheng, Xu Yongcai, Shanghai Xinyuantong Information Technology Co., Ltd., Hangzhou Xushengcheng Investment Partnership (Limited Partnership), and Cai Chi jointly signed the "Limited Partnership Agreement of Shanghai Proxima Phase IV Venture Capital Partnership (Limited Partnership)" (hereinafter referred to as the "Partnership Agreement"). According to the "Partnership Agreement", the company serves as a limited partner with its own capital of RMB 2,000 Ten thousand yuan is invested to subscribe for investment fund shares, and the subscribed capital contribution ratio accounts for 6.45%. For details, please refer to the "Announcement on Joint Investment and Establishment of Funds with Professional Investment Institutions" disclosed by the company on the cninfo.com (http://www.cninfo.com.cn) on May 12, 2026 (announcement number: 2026-025).

2. Progress of joint investment with professional investment institutions

Recently, through consensus among all partners, Shanghai Proxima Phase IV Venture Capital Partnership (Limited Partnership) (hereinafter referred to as the "Partnership") decided to increase capital of the partnership and signed the revised "Shanghai Proxima Phase IV Venture Capital Partnership (Limited Partnership) Limited Partnership Agreement". The progress this time is as follows:

1. The total target subscribed capital contribution of the partnership increased from RMB 750 million to RMB 1 billion, and the total subscribed capital contribution of all partners increased from RMB 310 million to RMB 416 million.

2. Shanghai Future Qidian Private Equity Investment Fund Partnership (Limited Partnership) has a newly subscribed capital contribution of RMB 26.5 million; Hangzhou Xushengcheng Investment Partnership (Limited Partnership) has a newly subscribed capital contribution of RMB 15 million; Hangzhou Linkong Equity Investment Co., Ltd. has a newly subscribed capital contribution of RMB 10.6 million.

3. The partnership introduced new partners. The Yangtze River Delta Venture Capital Guidance Fund Partnership (Limited Partnership) subscribed capital of RMB 103.9 million.

4. The original intention was for limited partners Naxin Holdings Co., Ltd., Sun Jiansheng and Xu Yongcai to withdraw from the investment.

As a limited partner, the company's capital contribution of RMB 20 million from its own capital remains unchanged, and the proportion of subscribed capital is changed from 6.45% to 4.808%.

The basic information of the above-mentioned new limited partner Yangtze River Delta Venture Capital Guidance Fund Partnership (limited partnership) is as follows:

1. Company name: Yangtze River Delta Venture Capital Guidance Fund Partnership (Limited Partnership)

2. Date of establishment: December 22, 2025

3. Registered address: Unit 364, Floor 3, No. 1699 Zhongke Road, China (Shanghai) Pilot Free Trade Zone

4. Executive partner: SDIC Chuanghe Yangtze River Delta (Shanghai) Venture Capital Management Co., Ltd.

5. Enterprise type: limited partnership

6. Unified social credit code: 91310000MAK4HG0U9X

The newly added limited partners have no related relationships or other interest arrangements with the company's controlling shareholders, actual controllers, shareholders holding more than 5% of the shares, directors, and senior managers; nor do they hold the company's shares directly or indirectly. None of the new limited partners shall be deemed to be persons subject to enforcement for breach of trust.

After the above changes are completed, the capital contributions subscribed by each partner are as follows:

Amount of capital subscribed

Serial number Partner name/Name Partner type Subscription ratio

(10,000 yuan)

1 Shanghai Proxima Business Services Partnership (Limited Partnership) General Partner 550 1.322%

Shanghai Future Qidian Private Equity Investment Fund Partnership (Limited

2 limited partners 10,400 25.000% partnership)

Yangtze River Delta Venture Capital Guidance Fund Partnership (Limited Partnership)

3 limited partners 10,390 24.976%

Guy)

4 Hangzhou Linkong Equity Investment Co., Ltd. Limited partner 4,160 10.000% 5 Shanghai Jingtou Equity Investment Fund Management Co., Ltd. Limited partner 4,000 9.615% 6 Shanghai Shibei High-tech Co., Ltd. Limited partner 4,000 9.615% 7 Hangzhou Xushengcheng Investment Partnership (Limited Partnership) Limited partner 2,500 6.010% 8 Enwei Pharmaceutical Co., Ltd. Limited partner 2,000 4.808% 9 Zhao Jianlun Limited partner 1,500 3.606% 10 Shanghai Xinyuantong Information Technology Co., Ltd. Limited partner 1,400 3.365% 11 Cai Chi Limited partner 700 1.683%

Total - 41,600 100%

3. Other instructions

The partnership is still in the fundraising stage and needs to complete the industrial and commercial change registration procedures and the China Securities Investment Fund Industry Association filing. There is uncertainty in the implementation process. Due to the long investment cycle and low liquidity of the partnership, the company may face a longer investment return period for this investment; during the operation process, the partnership will be affected by various factors such as macroeconomics, industry cycles, market changes, and the operating conditions of the investment targets, and there may be risks of investment projects not realizing expected returns or investment failure. The company will perform its information disclosure obligations in a timely manner and strictly in accordance with relevant regulations based on subsequent progress. Investors are advised to pay attention to investment risks.

4. Documents for reference

1. The newly signed "Limited Partnership Agreement of Shanghai Proxima Phase IV Venture Capital Partnership (Limited Partnership)"

Announcement hereby

Enwei Pharmaceutical Co., Ltd. Board of Directors

July 6, 2026